METABOLIC HEALTH EXPERT SHARES INSIGHTS ON HEALTHY AGEING AND GROWING PUBLIC INTEREST IN THE FIELD
With
David Beard,
Senior Exercise Physiologist,
Metabolic Health Specialist, HFRC,
Nedlands, Western Australia &
Chair Western Australia Chapter
Exercise and Sports Science Australia (ESSA)
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Nedlands, Western Australia | April 2025
David Beard is a highly experienced Exercise Physiologist with a specialisation in metabolic health and healthy aging. He has spent over 40 years in this profession, even before exercise physiology was formally recognised as a discipline. His extensive background includes over a decade of working in aged care and a strong focus on adult health and fitness. David has authored a book on healthy aging and dedicated the last 10 to 12 years to advancing his expertise in metabolic health issues such as diabetes, weight loss, and inflammatory conditions. He is a co-owner of HFRC in Nedlands, Western Australia, where he has worked for nearly a decade.
A pivotal moment in David’s career occurred when he became one of the first exercise physiologists to work in the aged care sector, making significant contributions to the health of older adults. Passionate about the benefits of exercise and its impact as individuals age, David focuses on improving clients’ metabolic health through personalised strategies involving exercise, nutrition, and lifestyle modifications.
In his role as State Chair of Exercise and Sports Science Australia in WA, David advocates for greater recognition of the profession’s value in managing chronic health conditions. He believes that raising public awareness of metabolic health is essential, as it empowers individuals to understand how their daily choices significantly affect their long-term well-being. Through education and support, David strives to help others lead healthier, more active lives, particularly as they navigate the challenges of aging.
Source: Written by AUDIENCED from transcript
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
-
Child Dental Benefits Schedule needing greater awareness
Since its launch in 2014, the Child Dental Benefits Schedule has seen a gradual increase in participation year on year. The impact of COVID-19 and related shutdowns saw participation fall sharply in 2020. Though it increased 2021, the national target of 41% participation was not reached in 2021-2022, with the total (35.4%) more than three percent below 2018 participation rates.
In an opinion segment, Australian Health Journal spoke with Abano Healthcare Group Clinical Director, Dr Fred Calavassy, with over 30 years of clinical experience, about his observations of the Child Dental Benefits Scheme ways to increasing participation rates.
